| Literature DB >> 29690915 |
Hsiao-Feng Chou1, Yu-Hung Wu2, Che-Sheng Ho3, Yu-Hsuan Kao4.
Abstract
BACKGROUND: This study aimed to evaluate the demographic, clinical features, laboratory data, pathology and other survey in pediatric patients with cryofibrinogenemia.Entities:
Keywords: Central nervous system; Children; Cryofibrinogenemia
Mesh:
Year: 2018 PMID: 29690915 PMCID: PMC5937801 DOI: 10.1186/s12969-018-0249-6
Source DB: PubMed Journal: Pediatr Rheumatol Online J ISSN: 1546-0096 Impact factor: 3.054
Clinical symptoms and demographic features children
| Case | 1 | 2 (primary) | 3 | 4 | 5 | 6 | 7 | 8 | Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sex | M | F | F | F | M | F | F | F | Female/male ratio 3:1 | |||||||||
| Age of onset (yrs) | 9.4 | 13.6 | 11.4 | 9.6 | 2.5 | 12.4 | 18.5 | 14.6 | Mean (SD) age at on set (yrs) | |||||||||
| Age at diagnosis (yrs) | 9.6 | 13.8 | 11.6 | 10.6 | 4 | 13.6 | 18.6 | 17.1 | Mean (SD) at diagnosis (yrs) | |||||||||
| Expired on (yrs) | 10.4 | Loss to follow up | 12.1 | 10.8 | (−) | (−) | 19 | 17.6 | ||||||||||
| Clinical symptoms | All patients | |||||||||||||||||
| Initial/Total | Initial, n | Total, n | ||||||||||||||||
| Myalgia | (+) | (+) | (+) | (+) | (+) | (+) | (+) | (+) | (−) | (−) | (−) | (+) | (−) | (+) | (+) | (+) | 5 | 7 |
| Fever | (−) | (+) | (−) | (+) | (−) | (+) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (+) | (−) | (−) | 0 | 4 |
| Arthralgia | (+) | (+) | (+) | (+) | (+) | (+) | (+) | (+) | (+) | (+) | (+) | (+) | (−) | (+) | (+) | (+) | 7 | 8 |
| Skin manifestations | ||||||||||||||||||
| Purpura | (−) | (+) | (+) | (+) | (−) | (+) | (+) | (+) | (−) | (+) | (−) | (+) | (+) | (+) | (−) | (+) | 3 | 8 |
| Raynaud phenomenon | (−) | (+) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | 0 | 1 |
| Skin necrosis or ulceration | (−) | (+) | (−) | (−) | (−) | (+) | (−) | (−) | (+) | (+) | (−) | (−) | (−) | (+) | (−) | (+) | 1 | 5 |
| Livedo reticularis | (−) | (+) | (−) | (−) | (+) | (+) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (+) | (−) | (−) | 1 | 3 |
| Urticaria | (−) | (−) | (+) | (+) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (+) | (+) | (+) | 2 | 3 |
| Gangrene | (−) | (+) | (−) | (−) | (−) | (+) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (+) | (−) | (+) | 0 | 4 |
| Sensitivity to cold | (−) | (−) | (+) | (+) | (−) | (−) | (−) | (+) | (−) | (−) | (−) | (+) | (−) | (+) | (−) | (+) | 1 | 5 |
| Ecchymosis | (−) | (+) | (−) | (−) | (−) | (+) | (−) | (+) | (−) | (+) | (−) | (+) | (+) | (+) | (−) | (+) | 1 | 7 |
| Neurological involvement | ||||||||||||||||||
| Muscle weakness | (+) | (+) | (−) | (+) | (+) | (+) | (+) | (+) | (−) | (+) | (−) | (+) | (−) | (+) | (−) | (+) | 3 | 8 |
| Numbness | (−) | (+) | (−) | (−) | (−) | (+) | (−) | (+) | (−) | (−) | (−) | (+) | (−) | (+) | (−) | (+) | 0 | 6 |
| Headache | (−) | (+) | (−) | (+) | (+) | (+) | (−) | (+) | (−) | (−) | (+) | (+) | (+) | (+) | (+) | (+) | 4 | 7 |
| Vertigo | (−) | (−) | (−) | (+) | (−) | (+) | (−) | (−) | (−) | (−) | (−) | (+) | (−) | (+) | (+) | (+) | 1 | 5 |
| Dizziness | (−) | (+) | (−) | (+) | (+) | (+) | (−) | (+) | (−) | (−) | (+) | (+) | (+) | (+) | (+) | (+) | 4 | 7 |
| Seizure | (−) | (−) | (−) | (−) | (−) | (+) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (+) | (−) | (+) | 0 | 3 |
| Blurred vision | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (+) | (+) | (+) | (−) | (+) | 1 | 3 |
| Urinary retention | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (+) | 0 | 1 |
| Others | ||||||||||||||||||
| Dyspnea | (+) | (+) | (−) | (−) | (+) | (+) | (−) | (+) | (−) | (+) | (−) | (+) | (−) | (+) | (−) | (+) | 2 | 7 |
| Chest pain | (+) | (+) | (−) | (−) | (+) | (+) | (−) | (+) | (−) | (+) | (−) | (+) | (−) | (+) | (−) | (+) | 2 | 7 |
| Abdominal pain | (+) | (+) | (−) | (+) | (+) | (+) | (−) | (−) | (−) | (+) | (+) | (+) | (−) | (+) | (−) | (+) | 3 | 7 |
| Hematochezia | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (+) | (−) | (+) | (−) | (−) | (−) | (+) | 0 | 3 |
| Menorrhea | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (+) | 0 | 1 |
| Bone pain | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (+) | (+) | 1 | 1 |
| Insomnia | (−) | (+) | (−) | (+) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (+) | (−) | (+) | (−) | (+) | 0 | 5 |
Fig. 1a) Extensive purpura and gangrene on the left foot (Case 7). b) Ecchymosis and swelling on the left foot (Case 3). c) Ulcer on the buttocks (Case 3)
Systemic involvement and underline disease
| Case No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | No. Abnormal/Total | % |
|---|---|---|---|---|---|---|---|---|---|---|
| Skin biopsy | (+) | (−) | ND | ND | (+) | ND | ND | (−) | 2/4 | 50 |
| Renal involvement | 3/8 | 37.5 | ||||||||
| Proteinuria | (−) | (−) | (−) | (−) | (+) | (+) | (−) | (−) | 2/8 | 25 |
| Hematuria | (−) | (−) | (−) | (+) | (+) | (+) | (−) | (−) | 3/8 | 37.5 |
| Renal insufficiency | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (+) | 1/8 | 12.5 |
| Arthritis | (+) | (+) | (+) | (+) | (+) | (+) | (+) | (+) | 8/8 | 100 |
| Thrombotic events | (−) | (−) | (+) | (+) | (−) | (+) | (+) | (+) | 5/8 | 62.5 |
| Angiogram | ND | ND | (+) | (+) | ND | (+) | ND | (+) | 4/4 | 100 |
| Respiratory involvement | ||||||||||
| Pulmonary embolism | (+) | ND | (−) | ND | (−) | ND | (−) | ND | 1/4 | 25 |
| ARDS | (+) | (−) | (+) | (+) | (−) | (−) | (+) | (−) | 4/8 | 50 |
| Neurological involvement | ||||||||||
| Multineuritis | (+) | (−) | (+) | ND | (−) | (−) | (−) | (+) | 3/7 | 42.9 |
| Brain MRI | (−) | (−) | (+) | (+) | ND | (−) | (+) | (+) | 4/7 | 57.1 |
| Spine MRI | ND | ND | (−) | ND | ND | ND | ND | (−) | 0/2 | 0 |
| SSEP | ND | (−) | (−) | ND | ND | (−) | ND | ND | 0/3 | 0 |
| EMG | ND | (−) | ND | ND | ND | ND | (+) | ND | 1/2 | 50 |
| EEG | ND | (+) | (−) | ND | ND | ND | (+) | (+) | 3/4 | 75 |
| BAEP | ND | (−) | ND | ND | ND | (−) | (−) | (+) | 1/4 | 25 |
| VEP | ND | ND | ND | ND | ND | ND | (+) | (+) | 2/2 | 100 |
| Associated disease | ||||||||||
| Autoimmune disease | CG | (−) | JIA | JIA | JIA, JDM, SLE | JIA | B, SLE, JIA | CM, JIA, B | 6/8 | 75 |
| HCV/HBV infection | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | 0 | 0 |
(+) = abnormal; (−) = normal; ND = not done
ARDS acute respiratory distress syndrome, NCV nerve conduction velocity, EMG electromyogram, SSEP somatosensory evoked potential, BAEP brainstem auditory evoked potential, VEP visual evoked potential, HCV hepatitis C virus infection, HBV hepatitis B virus infection, CG cryoglobulinemia, JIA juvenile idiopathic arthritis, JDM juvenile dermatomyositis, SLE systemic lupus erythematosus, B Behcet’s disease, CM Cutaneous mastocytosis
Immunological laboratory examinations
| Case | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | No. Positive/No. All checked | (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Cryofibrinogen | (+) | (+) | (+) | (+) | (+) | (+) | (+) | (+) | 8/8 | (100) |
| Cryoglobulin | (+) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | 0/8 | (0) |
| α1-antitrypsin | ND | ND | (−) | ND | ND | (−) | ND | (−) | 0/3 | (0) |
| PT/aPTT(initial) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | 0/8 | (0) |
| Bleeding time | (−) | ND | ND | ND | ND | ND | ND | ND | 0/1 | (0) |
| IgA | (−) | (−) | (−) | (−) | (−) | (−) | ND | (−) | 0/7 | (0) |
| Platelet count | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | 0/7 | (0) |
| vWF | ND | (−) | I | (−) | (−) | I | (−) | (−) | 2/7 | (28.5) |
| C3 | (−) | D | (−) | (−) | D | (−) | D | D | 4/8 | (50) |
| C4 | (−) | (−) | (−) | D | (−) | D | I | D | 4/8 | (50) |
| Protein C | I | (−) | (−) | I | I | (−) | I | I | 5/8 | (62.5) |
| Protein S | I | (−) | D | D | D | D | D | I | 7/8 | (87.5) |
| Anti-thrombin III | I | I | I | I | I | I | I | I | 8/8 | (100) |
| Lupus anticoagulant | (−) | ND | (+) | (−) | (+) | (−) | (−) | (−) | 2/7 | (28.5) |
| RA factor | (−) | (−) | (+) | (−) | (−) | (+) | (−) | (+) | 3/8 | (37.5) |
| Antinuclear Factor | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (+) | 1/8 | (12.5) |
| Anti-cardiolipin IgG | (−) | (−) | (−) | (−) | (+) | (−) | (−) | (−) | 1/8 | (12.5) |
| Anti-cardiolipin IgM | (−) | (−) | (−) | (−) | (+) | (−) | (−) | (−) | 1/8 | (12.5) |
| anti-ENA (all) | (−) | (−) | (−) | (−) | (+) | (−) | (−) | (−) | 1/8 | (12.5) |
| Anti CCP | ND | ND | ND | (−) | (−) | (−) | (−) | (−) | 0/5 | (0) |
| ANCA-C | (−) | (−) | ND | ND | (−) | (−) | (−) | (−) | 0/6 | (0) |
| ANCA-P | (−) | (−) | ND | ND | (−) | (−) | (−) | (−) | 0/6 | (0) |
| Anti-β2 GP1 IgG | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | 0/8 | (0) |
| Anti-β2 GP1 IgM | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | 0/8 | (0) |
| Anti-ds DNA | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | 0/8 | (0) |
| Anti-SSA | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | 0/8 | (0) |
| Anti-SSB | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | 0/8 | (0) |
CCP cyclic citrullinated peptide, ANCA-C cytoplasmic anti-neutrophil cytoplasmic antibody, ANCA-P peri-nuclear anti-neutrophil cytoplasmic antibody, Anti-β2 GP1 Anti-β2-glycoprotein I, ENA extractable nucleic antigen, SSA Sjögren’s-syndrome-related antigen-A, Anti-SSB Sjögren’s-syndrome-related antigen-B
Fig. 2Skin histopathology showed micro-thrombi and deposition within the lumen of blood vessel (a, b) (Case 7) (400X, H&E stain)
Fig. 3Angiogram demonstrated narrowing on the right femoral artery (black arrow) (Case 7; a) and incomplete obstruction of medium-sized arteries on the knee (white arrow) (Case 4; b)
Fig. 4Brain magnetic resonance imaging (MRI). a) MR angiogram showed right vertebral artery narrowing (arrow) (Case 3). b) Axial T2-weighted flair MRI imaging demonstrated hyper-intense lesion on the peri-ventricular white matter (TR/TE: 9002/135.4 ms) (Case 3). c–f) Acute hemorrhagic encephaomyelitis (Case 8). Axial T2-weighted flair showed multiple hyper-intense with central hypo-intense lesions on the thalamus and white matter (T1-weighted flair: TR/TE: 2000/20 ms; T2-weighted flair: TR/TE: 8000/125 ms; ADC and DWI: TR/TE: 6000/72.89 ms)